Deerfield Management Company L.P. Series C Raises Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Deerfield Management Company L.P. Series C lifted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 135.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 109,536 shares of the medical instruments supplier’s stock after acquiring an additional 62,945 shares during the quarter. Deerfield Management Company L.P. Series C’s holdings in AngioDynamics were worth $663,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of ANGO. Acadian Asset Management LLC grew its stake in AngioDynamics by 11.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,012,186 shares of the medical instruments supplier’s stock worth $5,940,000 after purchasing an additional 107,764 shares in the last quarter. Armistice Capital LLC acquired a new stake in AngioDynamics in the fourth quarter valued at approximately $6,272,000. Western Standard LLC lifted its stake in AngioDynamics by 878.5% in the first quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock worth $3,072,000 after acquiring an additional 469,906 shares during the last quarter. Fund 1 Investments LLC acquired a new position in AngioDynamics during the 4th quarter worth approximately $3,896,000. Finally, Cubist Systematic Strategies LLC increased its position in shares of AngioDynamics by 15.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 226,503 shares of the medical instruments supplier’s stock valued at $1,370,000 after purchasing an additional 29,669 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Analyst Upgrades and Downgrades

ANGO has been the subject of several recent analyst reports. Canaccord Genuity Group decreased their price objective on shares of AngioDynamics from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Wednesday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a report on Friday, September 20th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, AngioDynamics presently has an average rating of “Moderate Buy” and an average target price of $12.25.

AngioDynamics Trading Up 1.5 %

ANGO stock opened at $7.51 on Friday. The stock has a market cap of $300.81 million, a P/E ratio of -1.55 and a beta of 0.65. AngioDynamics, Inc. has a twelve month low of $5.26 and a twelve month high of $8.25. The company’s 50 day moving average is $7.50 and its two-hundred day moving average is $6.55.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.11. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The firm had revenue of $71.00 million for the quarter, compared to analyst estimates of $70.86 million. During the same period last year, the business earned $0.02 EPS. AngioDynamics’s revenue for the quarter was down 22.1% compared to the same quarter last year. On average, equities research analysts predict that AngioDynamics, Inc. will post -0.41 earnings per share for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.